301 related articles for article (PubMed ID: 29922880)
1. The effect of cessation of 2nd generation P
Witberg G; Bathish J; Bental T; Leshem-Lev D; Assali A; Kornowski R; Lev E
J Thromb Thrombolysis; 2018 Oct; 46(3):351-358. PubMed ID: 29922880
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y
Franchi F; Rollini F; Faz G; Rivas JR; Rivas A; Agarwal M; Briceno M; Wali M; Nawaz A; Silva G; Shaikh Z; Maaliki N; Fahmi K; Been L; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Baber U; Mehran R; Jennings LK; Bass TA; Angiolillo DJ
J Am Heart Assoc; 2020 Apr; 9(8):e015865. PubMed ID: 32306797
[TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
4. Effect of Alirocumab Added to High-Intensity Statin on Platelet Reactivity and Noncoding RNAs in Patients with AMI: A Substudy of the PACMAN-AMI Trial.
Ueki Y; Häner JD; Losdat S; Gargiulo G; Shibutani H; Bär S; Otsuka T; Kavaliauskaite R; Mitter VR; Temperli F; Spirk D; Stortecky S; Siontis GCM; Valgimigli M; Windecker S; Gutmann C; Koskinas KC; Mayr M; Räber L
Thromb Haemost; 2024 Jun; 124(6):517-527. PubMed ID: 37595625
[TBL] [Abstract][Full Text] [Related]
5. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
7. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
9. Course of platelet miRNAs after cessation of P2Y12 antagonists.
Jäger B; Stojkovic S; Haller PM; Piackova E; Kahl BS; Andric T; Vargas KG; Wojta J; Huber K
Eur J Clin Invest; 2019 Aug; 49(8):e13149. PubMed ID: 31172515
[TBL] [Abstract][Full Text] [Related]
10. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
12. Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Olivier CB; Schnabel K; Weber S; Zhou Q; Bode C; Moser M; Diehl P
J Thromb Thrombolysis; 2016 Jul; 42(1):84-9. PubMed ID: 26837379
[TBL] [Abstract][Full Text] [Related]
13. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
14. Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor.
Eisen A; Lerman-Shivek H; Perl L; Rechavia E; Leshem-Lev D; Zemer-Wassercug N; Dadush O; Kazum S; Codner P; Kornowski R; Lev EI
J Thromb Thrombolysis; 2015 Jul; 40(1):70-5. PubMed ID: 25481810
[TBL] [Abstract][Full Text] [Related]
15. P2Y
van der Sangen NM; Küçük IT; Ten Berg JM; Beijk MA; Delewi R; den Hartog AW; Appelman Y; Verouden NJ; Kikkert WJ; Henriques JP; Claessen BE
Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):637-645. PubMed ID: 35916833
[TBL] [Abstract][Full Text] [Related]
16. Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Shang LL; Guo DD; Zhao HY; Quan AJ; Cao PG
J Clin Pharm Ther; 2018 Jun; 43(3):342-347. PubMed ID: 29150850
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic comparison of low-dose ticagrelor to low-dose prasugrel in patients with prior myocardial infarction: the ALTIC-2 study.
Alexopoulos D; Sfantou D; Lianos I; Pappas C; Revela I; Triantafyllidi H; Ikonomidis I
Platelets; 2020 Aug; 31(6):812-814. PubMed ID: 31608799
[TBL] [Abstract][Full Text] [Related]
18. Increased platelet inhibition after switching from prasugrel to low-dose ticagrelor in Japanese patients with prior myocardial infarction.
Tateishi K; Saito Y; Kitahara H; Nakayama T; Fujimoto Y; Kobayashi Y
J Cardiol; 2020 May; 75(5):473-477. PubMed ID: 31718953
[TBL] [Abstract][Full Text] [Related]
19. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
[TBL] [Abstract][Full Text] [Related]
20. Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y
Rollini F; Franchi F; Singh K; Cho JR; Bhatti M; DeGroat C; Hu J; Aggarwal N; Alobaidi Z; Thano E; Ferrante E; Zenni M; Bass TA; Angiolillo DJ
Thromb Haemost; 2016 Nov; 116(6):1060-1069. PubMed ID: 27488362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
